Cessation of anticoagulation therapy following endovascular thrombus removal and stent placement for acute iliofemoral deep vein thrombosis

被引:12
作者
Sebastian, Tim [1 ]
Engelberger, Rolf P. [2 ,3 ]
Spirk, David [4 ]
Hakki, Lawrence O. [3 ]
Baumann, Frederic A. [1 ]
Spescha, Rebecca S. [1 ]
Kucher, Nils [1 ]
机构
[1] Univ Hosp Zurich, Clin Angiol, Raemistr 100, CH-8091 Zurich, Switzerland
[2] Cantonal Hosp Fribourg, Div Angiol, Fribourg, Switzerland
[3] Univ Bern, Fac Med, Bern, Switzerland
[4] Univ Bern, Inst Pharmacol, Bern, Switzerland
关键词
Anticoagulation; catheter-directed thrombolysis; deep vein thrombosis; post-thrombotic syndrome; venous stents; CATHETER-DIRECTED THROMBOLYSIS; POSTTHROMBOTIC SYNDROME; PULMONARY-EMBOLISM; ANTITHROMBOTIC THERAPY; VENOUS THROMBOSIS; PREVENTION; RIVAROXABAN; GUIDELINES; MANAGEMENT; WARFARIN;
D O I
10.1024/0301-1526/a000774
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: The optimal duration of anticoagulation therapy (AT) following catheter-based therapy of acute iliofemoral deep vein thrombosis (IFDVT) with stent placement is unknown. Theoretically, resolving the underlying obstructive iliac vein lesion by a stent may eliminate the main trigger for recurrence, the post-thrombotic syndrome (PTS), and the need for extended-duration AT. Patients and methods: From 113 patients with acute IFDVT who underwent endovascular thrombus removal and stent placement, we compared patency rates and clinical outcomes between 58 patients on limited-duration AT (3-12 month) and 55 patients on extended-duration AT (> 12 months). Results: Mean follow-up duration was 26 +/- 18 (range 377) months; it was 24 +/- 18 (range 3-69) months after cessation of AT in the limited-duration AT group. In comparison to patients with extended-duration AT, patients with limited-duration AT were younger (38 versus 54 years; p < 0.001), more often female (74 % versus 49 %; p = 0.01), and had less often prior venous thromboembolism (VTE) (9 % versus 35 %; p = 0.001). May-Thurner syndrome was more frequent in the limited-duration AT group (66 % versus 38 %; p = 0.004). Overall, primary and secondary patency rates at 24 months were 80 % (95 % CI, 70-87 %) and 95 % (95 % CI, 88-98 %), respectively, with no difference between the groups. Overall, 17 (15 %) patients developed recurrent VTE, of which 14 (82 %) events were thrombotic stent occlusions, and 13 (76 %) events occurred during AT. In the limited-duration AT group, 98 % patients were free from the PTS at two years with a VTE recurrence rate of 3.5 per 100 patient years after cessation of AT. Conclusions: In selected patients with acute IFDVT and patent venous stent, particularly in younger and otherwise healthy patients with MayThurner syndrome, it appears to be safe to discontinue AT 3-12 months after endovascular treatment.
引用
收藏
页码:331 / 339
页数:9
相关论文
共 36 条
[1]   Apixaban for Extended Treatment of Venous Thromboembolism [J].
Agnelli, Giancarlo ;
Buller, Harry R. ;
Cohen, Alexander ;
Curto, Madelyn ;
Gallus, Alexander S. ;
Johnson, Margot ;
Porcari, Anthony ;
Raskob, Gary E. ;
Weitz, Jeffrey I. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (08) :699-708
[2]  
Baglin T, 2012, J THROMB HAEMOST, V10, P1702, DOI [10.1111/j.1538-7836.2012.04806.x, 10.1111/j.1538-7836.2012.04662.x]
[3]   Post-thrombotic syndrome: a clinical review [J].
Baldwin, M. J. ;
Moore, H. M. ;
Rudarakanchana, N. ;
Gohel, M. ;
Davies, A. H. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 (05) :795-805
[4]   Oral Rivaroxaban for Symptomatic Venous Thromboembolism. [J].
Bauersachs, Rupert ;
Berkowitz, Scott D. ;
Brenner, Benjamin ;
Buller, Harry R. ;
Decousus, Herve ;
Gallus, Alex S. ;
Lensing, Anthonie W. ;
Misselwitz, Frank ;
Prins, Martin H. ;
Raskob, Gary E. ;
Segers, Annelise ;
Verhamme, Peter ;
Wells, Phil ;
Agnelli, Giancarlo ;
Bounameaux, Henri ;
Cohen, Alexander ;
Davidson, Bruce L. ;
Piovella, Franco ;
Schellong, Sebastian .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (26) :2499-2510
[5]   May-Thurner syndrome and other obstructive iliac vein lesions: Meaning, myth, and mystery [J].
Birn, Jeffrey ;
Vedantham, Suresh .
VASCULAR MEDICINE, 2015, 20 (01) :74-83
[6]   Systematic Review: Case-Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding Events Among Patients Treated for Venous Thromboembolism [J].
Carrier, Marc ;
Le Gal, Gregoire ;
Wells, Philip S. ;
Rodger, Marc A. .
ANNALS OF INTERNAL MEDICINE, 2010, 152 (09) :578-+
[7]   Acute iliofemoral deep vein thrombosis: Evaluation of underlying anatomic abnormalities by spiral CT venography [J].
Chung, JW ;
Yoon, CJ ;
Jung, SI ;
Kim, HC ;
Lee, W ;
Kim, YI ;
Jae, HJ ;
Park, JH .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2004, 15 (03) :249-256
[8]   Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism [J].
Coleman, Craig I. ;
Beyer-Westendorf, Jan ;
Bunz, Thomas J. ;
Mahan, Charles E. ;
Spyropoulos, Alex C. .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2018, 24 (04) :575-582
[9]   Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism The PADIS-PE Randomized Clinical Trial [J].
Couturaud, Francis ;
Sanchez, Olivier ;
Pernod, Gilles ;
Mismetti, Patrick ;
Jego, Patrick ;
Duhamel, Elisabeth ;
Provost, Karine ;
Sollier, Claire Bal Dit ;
Presles, Emilie ;
Castellant, Philippe ;
Parent, Florence ;
Salaun, Pierre-Yves ;
Bressollette, Luc ;
Nonent, Michel ;
Lorillon, Philippe ;
Girard, Philippe ;
Lacut, Karine ;
Guegan, Marie ;
Bosson, Jean-Luc ;
Laporte, Silvy ;
Leroyer, Christophe ;
Decousus, Herve ;
Meyer, Guy ;
Mottier, Dominique .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (01) :31-40
[10]   Early clinical outcomes of a novel rheolytic directional thrombectomy technique for patients with iliofemoral deep vein thrombosis [J].
Dopheide, Jorn F. ;
Sebastian, Tim ;
Engelberger, Rolf P. ;
Haine, Axel ;
Kucher, Nils .
VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE, 2018, 47 (01) :56-62